These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27097127)

  • 1. Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases.
    Convertino M; Das J; Dokholyan NV
    ACS Chem Biol; 2016 Jun; 11(6):1471-89. PubMed ID: 27097127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein misfolding in disease and small molecule therapies.
    Gomes CM
    Curr Top Med Chem; 2012; 12(22):2460-9. PubMed ID: 23339300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
    Hou ZS; Ulloa-Aguirre A; Tao YX
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Chaperones: Beyond Conformational Disorders.
    Leidenheimer NJ
    Handb Exp Pharmacol; 2018; 245():135-153. PubMed ID: 29071508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases.
    Naik S; Zhang N; Gao P; Fisher MT
    Curr Top Med Chem; 2012; 12(22):2504-22. PubMed ID: 23339304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology.
    Mahley RW; Huang Y
    J Med Chem; 2012 Nov; 55(21):8997-9008. PubMed ID: 23013167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules.
    Ulloa-Aguirre A; Conn PM
    Curr Drug Targets; 2016; 17(13):1471-81. PubMed ID: 26953247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
    Aymami J; Barril X; Rodríguez-Pascau L; Martinell M
    Pharm Pat Anal; 2013 Jan; 2(1):109-24. PubMed ID: 24236974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomics uncovering possible key players in F508del-CFTR processing and trafficking.
    Gomes-Alves P; Penque D
    Expert Rev Proteomics; 2010 Aug; 7(4):487-94. PubMed ID: 20653505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of protein-folding diseases at a glance.
    Valastyan JS; Lindquist S
    Dis Model Mech; 2014 Jan; 7(1):9-14. PubMed ID: 24396149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological chaperones: a potential therapeutic treatment for conformational diseases].
    Mendre C; Mouillac B
    Med Sci (Paris); 2010; 26(6-7):627-35. PubMed ID: 20619166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening methods for identifying pharmacological chaperones.
    Shin MH; Lim HS
    Mol Biosyst; 2017 Mar; 13(4):638-647. PubMed ID: 28265599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator.
    Namkung W; Kim KH; Lee MG
    Gastroenterology; 2005 Dec; 129(6):1979-90. PubMed ID: 16344066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein misfolding diseases: Prospects of pharmacological treatment.
    Gámez A; Yuste-Checa P; Brasil S; Briso-Montiano Á; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
    Clin Genet; 2018 Mar; 93(3):450-458. PubMed ID: 28671287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel pharmacological strategies to treat cystic fibrosis.
    Hanrahan JW; Sampson HM; Thomas DY
    Trends Pharmacol Sci; 2013 Feb; 34(2):119-25. PubMed ID: 23380248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin.
    Maiti P; Manna J; Veleri S; Frautschy S
    Biomed Res Int; 2014; 2014():495091. PubMed ID: 25386560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unravelling druggable signalling networks that control F508del-CFTR proteostasis.
    Hegde RN; Parashuraman S; Iorio F; Ciciriello F; Capuani F; Carissimo A; Carrella D; Belcastro V; Subramanian A; Bounti L; Persico M; Carlile G; Galietta L; Thomas DY; Di Bernardo D; Luini A
    Elife; 2015 Dec; 4():. PubMed ID: 26701908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoplasmic Reticulum-Targeted Subunit Toxins Provide a New Approach to Rescue Misfolded Mutant Proteins and Revert Cell Models of Genetic Diseases.
    Adnan H; Zhang Z; Park HJ; Tailor C; Che C; Kamani M; Spitalny G; Binnington B; Lingwood C
    PLoS One; 2016; 11(12):e0166948. PubMed ID: 27935997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction: molecular chaperones of the ER: their role in protein folding and genetic disease.
    Brooks DA
    Semin Cell Dev Biol; 1999 Oct; 10(5):441-2. PubMed ID: 10597626
    [No Abstract]   [Full Text] [Related]  

  • 20. Biological properties of D- and L-1-deoxyazasugars.
    Kato A; Kato N; Kano E; Adachi I; Ikeda K; Yu L; Okamoto T; Banba Y; Ouchi H; Takahata H; Asano N
    J Med Chem; 2005 Mar; 48(6):2036-44. PubMed ID: 15771446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.